| Autor: |
Chavey WE; University of Michigan Health System, Ann Arbor, MI, USA., Hogikyan RV; University of Michigan Health System, Ann Arbor, MI, USA., Van Harrison R; University of Michigan Health System, Ann Arbor, MI, USA., Nicklas JM; University of Michigan Health System, Ann Arbor, MI, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
American family physician [Am Fam Physician] 2017 Jan 01; Vol. 95 (1), pp. 13-20. |
| Abstrakt: |
Heart failure is an increasingly common condition resulting in high rates of morbidity and mortality. For patients who have heart failure and reduced ejection fraction, randomized clinical trials demonstrate consistent mortality benefit from angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct-acting vasodilators, beta blockers, and aldosterone antagonists. Additionally, some data show benefits from two new classes of drugs: angiotensin receptor blocker/neprilysin inhibitor and sinus node modulator. Diuretics and digoxin can be used as needed for symptom control. Statins are not recommended solely for treatment of heart failure. Implantable cardioverter-defibrillators and biventricular pacemakers improve mortality and function in selected patients. For patients who have been hospitalized for heart failure, disease management programs and telemonitoring can reduce hospitalizations and mortality. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
